-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

Benzinga·10/28/2026 15:42:21
Listen to the news
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.